Cantex Pharmaceuticals – Developing Cancer Therapies
Dr. Steve Marcus, CEO of Cantex Pharmaceuticals, a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed discusses 2 clinical trials for azeliragon, an orally active, small molecule, antagonist of the receptor for advanced glycation end products (RAGEs) in various cancers.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Cancer. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Cancer and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Cancer?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Stephen G. Marcus, M.D., is a medical oncologist and pharmaceutical executive who has led the development of several profitable pharmaceutical and biotechnology products. Dr. Marcus led the development of Betaseron, the first effective treatment for multiple sclerosis, and was instrumental in the development of Intron A, Temodar, Fludara, and brand-equivalent Paclitaxel.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
